Prevention and treatment of osteoporosis in inflammatory bowel disease

Inflamm Bowel Dis. 2006 Aug;12(8):797-813. doi: 10.1097/00054725-200608000-00016.

Abstract

The following are guidelines for evaluation and consideration for treatment of patients with inflammatory bone disease (IBD) after bone mineral density (BMD) measurements. The Crohn's & Colitis Foundation of America (CCFA) has indicated that its recommendations are intended to serve as reference points for clinical decision-making, not as rigid standards, limits, or rules. They should not be interpreted as quality standards.

Publication types

  • Review

MeSH terms

  • Absorptiometry, Photon
  • Bone Density / drug effects*
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Diseases, Metabolic / diagnosis
  • Bone Remodeling / physiology
  • Calcium, Dietary / therapeutic use
  • Fractures, Spontaneous / etiology
  • Glucocorticoids / adverse effects
  • Humans
  • Inflammatory Bowel Diseases / complications*
  • Osteoporosis* / etiology
  • Osteoporosis* / prevention & control
  • Osteoporosis* / therapy
  • Risk Factors
  • Vitamin D / therapeutic use

Substances

  • Bone Density Conservation Agents
  • Calcium, Dietary
  • Glucocorticoids
  • Vitamin D